Immunocore Holdings plc (IMCR)
IMCRNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$30.59
-1.54 (-4.79%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $1.63bn
- P/E
- –
- EPS, last 4 quarters
- $-0.6500
- Dividend yield
- –
- Day range
- –
- 52-week range
- $27.50 to $40.71
- Average volume
- 461.6k
- Previous close
- $32.13
Analysts
6 coveringBuy3 buy, 3 hold, 0 sell
Targets a year out average $56.50, +84.7% from here
Earnings
next estimate $-0.1300Next report
Dec 2025
-114.3%
Mar 2026
+196.2%
Jun 2026
-100.0%
Sep 2026
-133.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $103.69m | $104.48m | $106.68m | $115.93m |
| Gross profit | $103.18m | $101.78m | $106.24m | $114.84m |
| Operating income | -$7.17m | -$19.69m | $7.28m | -$3.00m |
| Net income | -$177.0k | -$30.06m | $12.97m | -$808.0k |
Last four quarters: revenue $430.77m, margin -4.2%, free cash flow -$41.15m
News
8 latest- Immunocore Holdings plc Reports Q3 2026 Financial ResultsFintel · 3 days ago
- Immunocore Hits Enrollment Target in Kimmtrak Label Expansion StudyZacks · Sep 15, 2026
- Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?Zacks · Aug 25, 2026
- IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More MomentumZacks · Aug 10, 2026
- Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?Zacks · Aug 10, 2026
- IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS MissZacks · Aug 10, 2026
- Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y RevenuesZacks · Aug 7, 2026
- Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?Zacks · Aug 7, 2026
The company
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease - designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company's most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in 39 countries, including the United States, European Union, Canada, Australia, and the United Kingdom.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- immunocore.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.